Nortech Systems's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 52.4.
Nortech Systems's Days Inventory for the
three
months ended in Mar. 2026 was 78.83.
Nortech Systems's Days Payable for the
three
months ended in Mar. 2026 was 48.9.
Therefore, Nortech Systems's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 82.33.
Nortech Systems (NAS:NSYS) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Nortech Systems Cash Conversion Cycle Related Terms
Nortech Systems Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Nortech Systems's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSYS vs ELUT, SRTS, MYO: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Nortech Systems's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nortech Systems Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nortech Systems's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Nortech Systems's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Nortech Systems's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nortech Systems (NSYS) has a Cash Conversion Cycle of 82.33 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nortech Systems and its competitors.
Is Nortech Systems' Cash Conversion Cycle too high?
Nortech Systems' current Cash Conversion Cycle is 82.33. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Nortech Systems' value of 82.33 is 47.5% below this industry median. Overall, Nortech Systems has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nortech Systems' Cash Conversion Cycle compare to ELUT and SRTS?
Nortech Systems' Cash Conversion Cycle of 82.33 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Nortech Systems' value of 82.33 is 47.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nortech Systems's current Cash Conversion Cycle of 82.33 is 47.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nortech Systems and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nortech Systems's current Cash Conversion Cycle is 82.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nortech Systems stock overvalued right now?
Based on GuruFocus' analysis, Nortech Systems (NSYS) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.24, compared to a current price of $16.10 — trading 74.2% above its estimated fair value. The current Cash Conversion Cycle is 82.33 and 47.5% below the Medical Devices & Instruments industry median of 156.96. Nortech Systems' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Nortech Systems (NSYS), the current Cash Conversion Cycle is 82.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nortech Systems (NSYS) Overvalued in 2026?
Based on GuruFocus' analysis, Nortech Systems stock appears to be overvalued.
The current stock price of $16.10 is trading 74.2% above its estimated GF Value™ of $9.24.
GuruFocus considers Nortech Systems to be Significantly Overvalued.
Key valuation signals for NSYS:
Cash Conversion Cycle: 82.33
GF Value™: $9.24 vs. price of $16.10 (74.2% above fair value)
Industry Position: 47.5% below the Medical Devices & Instruments median
No single metric tells the full story. See the NSYS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
54GF Score
Get the complete analysis for NSYS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSYS has been successfully added to your 
